

Electronic Acknowledgement Receipt

EFS ID:	7735758
Application Number:	09993647
International Application Number:	
Confirmation Number:	1010
Title of Invention:	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
First Named Inventor/Applicant Name:	Bernd Riedl
Customer Number:	23599
Filer:	Csaba Henter/Caitlin Sickler
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	BAYER 18A
Receipt Date:	03-JUN-2010
Filing Date:	27-NOV-2001
Time Stamp:	10:43:27
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P263-STORMETAL- RAFOncogenesCarcinogenesis. pdf	877572 <small>72d10c5aca370cd33be72c814c5cb11e2fa dd47b</small>	no	8

Warnings:

Information:

2	NPL Documents	P263a-Strumberg-Drugs-Today-v41-p773.pdf	991014	no	12
			55d9c13df4dd2c07df62aa2cf752c14843538d86		
Warnings:					
Information:					
3	NPL Documents	P264StrumbergetalPhaseIAndPharmacokineticsStudyOftheNovelRafKinaseandVascularEndothelial.pdf	838003	no	9
			84ef24a4bd6568dab0c90a4b48342966dfd13ca		
Warnings:					
Information:					
4	NPL Documents	P265-STRUMBERGETAL-PhaseIAdvancedMetastaticCancer.pdf	194994	no	2
			fab1c88e82f4cdc7c133aa995b9041e3cd535fed		
Warnings:					
Information:					
5	NPL Documents	P266-StrumbergResultsofPhaseIPharmacokineticandPharmacodynamicStudiesoftheRafKinaseInhibitor.pdf	246107	no	2
			07393a003ea4ce16680ebf7c86d10adf44219585		
Warnings:					
Information:					
6	NPL Documents	P266a-StrumbergetalSorafenibNeutrophilictherapieoption.pdf	366757	no	4
			bbca3b04424665006f29a6339ea1b3fd7907ab0		
Warnings:					
Information:					
7	NPL Documents	P267-SUZUKI-ET-AL-Roleofp38.pdf	239751	no	5
			49b4b00fa717fc327d4ac9b983afb781c8a56f31		
Warnings:					
Information:					
8	NPL Documents	P268-SwarbricketalEncycloPharmTech.pdf	236492	no	4
			96e6f286e354467aa431142deb567ee1a0fca7f6		
Warnings:					
Information:					
9	NPL Documents	P269-SWARTGUIDOWMINTERNATIONALMELANOMARESEARCH.pdf	262646	no	3
			a931120eb31469819fe85f79e612b45d7a5a9ec1		
Warnings:					
Information:					
10	NPL Documents	P270-TABELLINIETALNOVEL2SUBSTITUTED.pdf	2066930	no	9
			c1bc60c415dd640b44bfce36442468b96ad082f4		
Warnings:					
Information:					

11	NPL Documents	P271-TAKIMOTO-SafetyAntiTumorActivitySorafenib.pdf	515720 3429af0e7270d38dec10a979f9a03c7fcefe800a	no	14
Warnings:					
Information:					
12	NPL Documents	P272-TAMM-HypoziolInducedInterleukin-6.pdf	878894 aa78315dc0b302e835367be751fcd2106c223e46	no	9
Warnings:					
Information:					
13	NPL Documents	P273-TANAKAETAL-HepatocellularCarcinoma.pdf	940709 7ea206adc553f0d6621d7a470bed334e03917459	no	8
Warnings:					
Information:					
14	NPL Documents	P274-TANG-InhaleNitricOxideAttenuatesPul.pdf	297401 2f4463d8656617a40d9912c3837d242bc3d63b52	no	9
Warnings:					
Information:					
15	NPL Documents	P275-Tarzia-ChemicalAbstracts.pdf	135107 b4134641be3446aea7f58b212fc81b2a08ca6100	no	1
Warnings:					
Information:					
16	NPL Documents	P275a-Teknos-et-al-Head-Neck-v24-p1004.pdf	143744 ff25fa995d4ccbd2a1248db603988d2a5d374006	no	8
Warnings:					
Information:					
17	NPL Documents	P276-Thaimattam3D-QSA.pdf	962868 0db4ae09edc280399bdb61ec5a693cf1eccdd1690	no	11
Warnings:					
Information:					
18	NPL Documents	P277-THELEN-VEGF-DPromotesTumorGrowth.pdf	2122609 b87b06609b873cb6da2118bf2358b1ecf2418a2	no	11
Warnings:					
Information:					
19	NPL Documents	P278-ThompsonRecentProgressinTargetingtheRaf-MEK-ERKPathwaywithInhibitorsinCancerDrugDiscovery.pdf	656952 ffe349fad7fad94da688b16ce09be0543cc15cd	no	8
Warnings:					
Information:					

20	NPL Documents	P279-TONGETAL- PharmacodynamicMonitoring. pdf	883954 bb93e1bc6024436f1bb7bde2299f13193c4 165ab	no	8
----	---------------	---	--	----	---

Warnings:

Information:

Total Files Size (in bytes):	13858224
-------------------------------------	----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.